stockrow
Friday 6 November 2026
Export CGTX’s income statement to Excel — free account
Cognition Therapeutics, Inc.
CGTX Healthcare Biotechnology
- EPS
- +63.6%
- Free cash flow
- +45.4%
Quarter to June 2026, against a year earlier
0.69
0.05
+7.81%
Follow CGTX
Alert me
Cognition Therapeutics, Inc. (CGTX) P/E ratio
Cognition Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.8× (November 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.8×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CGTX Cognition Therapeutics, Inc. | n/m |
| GOSS Gossamer Bio, Inc. compare | n/m |
| NORD Nordicus Partners Corporation compare | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| SPRO Spero Therapeutics, Inc. compare | 7.4× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)